Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 4/20 | 0.66 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.66 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.59 |
| ▸ | TLR4 | O00206 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16902845 | 1.00 | CHRNB4 (0.66) | CHRNB4CHRNA3CHRNB2CHRNA4TLR4 | |
| SCHEMBL29639202 | 1.00 | CHRNB4 (0.66) | CHRNB4CHRNA3CHRNB2CHRNA4TLR4 | |
| SCHEMBL22816951 | 0.93 | CHRNB4 (0.62) | CHRNB4CHRNA3CHRNB2CHRNA4TLR4 | |
| SCHEMBL27996245 | 0.91 | CHRNB4 (0.60) | CHRNB4CHRNA3CHRNB2CHRNA4TLR4 | |
| SCHEMBL3098610 | 0.89 | CHRNB4 (0.57) | CHRNB4CHRNA3CHRNB2CHRNA4APP | |
| SCHEMBL21944935 | 0.88 | CHRNB4 (0.54) | CHRNB4CHRNA3CHRNB2CHRNA4TLR4 | |
| SCHEMBL21944829 | 0.88 | CHRNB4 (0.54) | CHRNB4CHRNA3CHRNB2CHRNA4TLR4 | |
| SCHEMBL3103428 | 0.87 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNB2CHRNA4TLR4 | |
| SCHEMBL13096985 | 0.86 | CHRNB4 (0.55) | CHRNB4CHRNA3CHRNB2CHRNA4TLR4 | |
| SCHEMBL20744518 | 0.82 | GRIN2D (0.55) | CHRNB4CHRNA3CHRNB2CHRNA4KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114436978-B | Antifungal compound and application thereof | 中国人民解放军海军军医大学 | 2024-06-18 | — | — | CN | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| CN-114436978-A | Antifungal compound and application | 中国人民解放军海军军医大学 | 2022-05-06 | — | — | CN | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| CN-107207444-B | Bicyclic compounds | 武田药品工业株式会社 | 2020-07-24 | — | — | CN | disclosed |
| EP-3225618-B1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-10301292-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-28 | — | — | US | disclosed |
| US-10252997-B2 | Monocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3279183-A1 | MONOCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-3279183-A1 | MONOCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
| US-20180002322-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-04 | — | — | US | disclosed |
| EP-3225618-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-10-04 | — | — | EP | disclosed |
| CN-107207444-A | Bicyclic compound | 武田药品工业株式会社 | 2017-09-26 | — | — | CN | disclosed |
| US-20160060260-A1 | BROMODOMAIN INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060260-A1 | BROMODOMAIN INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060260-A1 | BROMODOMAIN INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-03-03 | — | — | US | disclosed |
| WO-2016033416-A1 | BROMODOMAIN INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016033416-A1 | BROMODOMAIN INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002322-A1 | BICYCLIC COMPOUND | ACACA, ACACB, ACAT1 | CHRNB4 4352/4885CHRNA3 3516/4885CHRNB2 4246/4885 |
| US-10301292-B2 | Bicyclic compound | ACACA, ACACB, ACAT1 | CHRNB4 4352/4885CHRNA3 3516/4885CHRNB2 4246/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | CHRNB4 3584/4885CHRNA3 3597/4885CHRNB2 3734/4885 |
| US-10252997-B2 | Monocyclic compound | FABP1, CPT1A, GOT2 | CHRNB4 4874/4885CHRNA3 4830/4885CHRNB2 4877/4885 |
| US-20160060260-A1 | BROMODOMAIN INHIBITORS FOR TREATING DISEASE | BRDT, BRPF3, BRWD1 | CHRNB4 2785/4885CHRNA3 2525/4885CHRNB2 2300/4885 |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | FABP1, CPT1A, GOT2 | CHRNB4 4874/4885CHRNA3 4830/4885CHRNB2 4877/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | CHRNB4 3584/4885CHRNA3 3597/4885CHRNB2 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.